LUF6000

LUF6000是人A3腺苷受体变构调节剂。

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 腺苷受体

研究领域 >> 心血管疾病

[1]. Gao ZG, Verzijl D, Zweemer A et al. Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol. 2011 Sep 15;82(6):658-68. doi: 10.1016/j.bcp.2011.06.017.

[2]. Szentmiklósi AJ, Cseppento A, Harmati G, Nánási PP. Novel trends in the treatment of cardiovascular disorders: site- and event- selective adenosinergic drugs. Curr Med Chem. 2011;18(8):1164-87.

[3]. Heitman LH, G?bly?s A, Zweemer AM, et al. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. J Med Chem. 2009 Feb 26;52(4):926-31.

[4]. Gao ZG, Ye K, G?bly?s A, et al. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol. 2008 Dec 12;8:20.

[5]. G?bly?s A, Gao ZG, Brussee J, et al. Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. J Med Chem. 2006 Jun 1;49(11):3354-61.

CGS 21680盐酸盐 | 瑞德南特 | ZM 241385 | CPI-444 | 2-(2-呋喃基)-7-(2-苯基乙基)-7H-吡唑并[4,3-e][1,2,4]噻唑并[1,5-c]嘧啶-5-胺 | Vipadenant | 伊曲茶碱 | 4-羟基-N-[4-甲氧基-7-(4-吗啉基)-2-苯并噻唑基]-4-甲基-1-哌啶甲酰胺 | AZD-4635 | 卡帕诺生 | 氯-IB-MECA | PSB-12379 | CD73-IN-1 | 匹利诺生 | 二羟丙茶碱